Iqvia (IQV) Scheduled to Post Earnings on Wednesday

Iqvia (NYSE:IQV) is scheduled to release its earnings data before the market opens on Wednesday, July 24th. Analysts expect Iqvia to post earnings of $1.39 per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Iqvia (NYSE:IQV) last released its earnings results on Wednesday, May 1st. The medical research company reported $1.53 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.41 by $0.12. Iqvia had a return on equity of 15.08% and a net margin of 2.35%. The firm had revenue of $2.68 billion for the quarter, compared to the consensus estimate of $2.67 billion. During the same period in the prior year, the business posted $1.34 earnings per share. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. On average, analysts expect Iqvia to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

NYSE IQV opened at $156.27 on Tuesday. The stock’s 50-day simple moving average is $152.12. Iqvia has a twelve month low of $104.90 and a twelve month high of $164.13. The stock has a market capitalization of $30.97 billion, a P/E ratio of 30.52, a PEG ratio of 1.89 and a beta of 0.87. The company has a debt-to-equity ratio of 1.69, a current ratio of 1.14 and a quick ratio of 1.14.

Several research firms recently weighed in on IQV. William Blair reiterated an “outperform” rating on shares of Iqvia in a research report on Wednesday, June 19th. Barclays set a $330.00 price target on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Monday, July 15th. Credit Suisse Group upped their price target on Adobe from $300.00 to $325.00 and gave the stock a “positive” rating in a research note on Wednesday, June 19th. Wolfe Research started coverage on Iqvia in a research note on Tuesday, April 2nd. They set a “market perform” rating for the company. Finally, Stifel Nicolaus set a $14.00 price target on Oasis Petroleum and gave the stock a “buy” rating in a research note on Wednesday, June 19th. Three equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. Iqvia presently has an average rating of “Buy” and a consensus target price of $156.18.

In other news, insider Ari Bousbib sold 96,000 shares of the stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $160.00, for a total value of $15,360,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kevin C. Knightly sold 46,080 shares of the stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $138.06, for a total value of $6,361,804.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 238,080 shares of company stock valued at $36,121,805. Insiders own 6.00% of the company’s stock.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Story: Gap Down Stocks

Earnings History for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.